The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박은정 | - |
dc.contributor.author | 김형진 | - |
dc.contributor.author | 정승민 | - |
dc.contributor.author | Yoon-Kyoung Sung | - |
dc.contributor.author | Han Joo Baek | - |
dc.contributor.author | Jisoo Lee | - |
dc.date.available | 2020-04-06T06:40:45Z | - |
dc.date.created | 2020-04-02 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 2093-940X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26195 | - |
dc.description.abstract | Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inflammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bDMARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert Consensus for the Use of bDMARDs Drugs for Inflammatory Arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한류마티스학회 | - |
dc.relation.isPartOf | 대한류마티스학회지 | - |
dc.title | The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus | - |
dc.title.alternative | The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.wosid | 000523561200002 | - |
dc.identifier.doi | 10.4078/jrd.2020.27.1.4 | - |
dc.identifier.bibliographicCitation | 대한류마티스학회지, v.27, no.1, pp.4 - 21 | - |
dc.identifier.kciid | ART002542537 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 21 | - |
dc.citation.startPage | 4 | - |
dc.citation.title | 대한류마티스학회지 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Han Joo Baek | - |
dc.subject.keywordAuthor | Expert consensus | - |
dc.subject.keywordAuthor | bDMARDs | - |
dc.subject.keywordAuthor | Inflammatory arthritis | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Ankylosing spondylitis | - |
dc.subject.keywordPlus | ANTITUMOR-NECROSIS-FACTOR | - |
dc.subject.keywordPlus | ACTIVE RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | B-VIRUS REACTIVATION | - |
dc.subject.keywordPlus | RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | - |
dc.subject.keywordPlus | RECEIVING CONCOMITANT METHOTREXATE | - |
dc.subject.keywordPlus | INTERLEUKIN-6 RECEPTOR INHIBITION | - |
dc.subject.keywordPlus | ADALIMUMAB PLUS METHOTREXATE | - |
dc.subject.keywordPlus | FACTOR MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | HBSAG-POSITIVE PATIENTS | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.